Search Result

Results for "

COVID-19 pneumonia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Complement System (3) Drug Intermediate (1) Interleukin Related (1) Isotope-Labeled Compounds (2) NOD-like Receptor (NLR) (1) SARS-CoV (8) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (7) Metabolic Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155876

NVP-DFV890 NLRP3 antagonist 2	NOD-like Receptor (NLR)	Infection Inflammation/Immunology
NVP-DFV890 is an orally administered, selective NLRP3 inhibitor. NVP-DFV890 directly binds to NLRP3, blocks maturation of pro-inflammatory cytokines IL-1β and IL-18, and inhibits pyroptotic cell death. NVP-DFV890 acts as an inducer of viral clearance, promoting earlier clearance of SARS-CoV-2. NVP-DFV890 can be used for the research of COVID-19 pneumonia and coronavirus-associated acute respiratory distress syndrome (CARDS) .

HY-P1717

AMY-101 Maximum Cited Publications 7 Publications Verification Cp40	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717B

AMY-101 acetate Maximum Cited Publications 7 Publications Verification Cp40 acetate	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717A

AMY-101 TFA Maximum Cited Publications 7 Publications Verification Cp40 TFA	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P991501

Meplazumab HcHAb18	ADC Antibody Transmembrane Glycoprotein SARS-CoV	Infection Cancer
Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a K_d of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer .

HY-P99810

Quisovalimab AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002	SARS-CoV	Infection Inflammation/Immunology
Quisovalimab (AVTX-002) is a human-derived monoclonal antibody against LIGHT (TNFSF14). Quisovalimab binds to LIGHT, blocks the signal transduction activity of LIGHT, reduces circulating LIGHT levels and attenuates pro-inflammatory effects. Quisovalimab can be used in research related to Crohn's disease, COVID-19-associated pneumonia and acute respiratory distress syndrome comorbidity .

HY-P99919

Efmarodocokin alfa 1 Publications Verification	Interleukin Related	Infection
Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .

HY-172223

3-Deazaguanosine C3Guo	SARS-CoV	Infection
3-Deazaguanosine (C3Guo) has potent antiviral activity against SARS-CoV-2 (EC₅₀: 1.14 μM, CC₅₀: >200 μM for Vero E6 cells). 3-Deazaguanosine prevents COVID-19 pneumonia .

HY-100442S1

Paquinimod-d5-1 ABR-215757-d₅-1; ABR 25757-d₅-1	SARS-CoV Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-100442S

Paquinimod-d5 ABR-215757-d₅; ABR 25757-d₅	SARS-CoV Isotope-Labeled Compounds	Metabolic Disease
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-112042

Aspirin Trelamine	Drug Intermediate	Infection Cardiovascular Disease Inflammation/Immunology
Aspirin Trelamine is a salicylic acid prodrug. Aspirin Trelamine has been used in research related to ischemic stroke, as well as COVID-19-associated acute respiratory distress syndrome (ARDS) and pneumonia .

Cat. No.	Product Name	Target	Research Area

HY-P1717

AMY-101 Maximum Cited Publications 7 Publications Verification Cp40	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717B

AMY-101 acetate Maximum Cited Publications 7 Publications Verification Cp40 acetate	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717A

AMY-101 TFA Maximum Cited Publications 7 Publications Verification Cp40 TFA	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991501

Meplazumab HcHAb18	ADC Antibody Transmembrane Glycoprotein SARS-CoV	Infection Cancer
Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a K_d of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer .

HY-P99810

Quisovalimab AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002	SARS-CoV	Infection Inflammation/Immunology
Quisovalimab (AVTX-002) is a human-derived monoclonal antibody against LIGHT (TNFSF14). Quisovalimab binds to LIGHT, blocks the signal transduction activity of LIGHT, reduces circulating LIGHT levels and attenuates pro-inflammatory effects. Quisovalimab can be used in research related to Crohn's disease, COVID-19-associated pneumonia and acute respiratory distress syndrome comorbidity .

HY-P99919

Efmarodocokin alfa 1 Publications Verification	Interleukin Related	Infection
Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .

Cat. No.	Product Name	Chemical Structure

HY-100442S1

Paquinimod-d5-1
Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

HY-100442S

Paquinimod-d5
Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.